PT Boehringer Ingelheim Indonesia (Indonesia)

Boehringer Ingelheim Indonesia is primarily engaged in pharmaceutical preparations, nec activity. Its headquarters is located in Dki Jakarta. The company was founded in 1997. Boehringer Ingelheim Indonesia is a subsidiary of Boehringer Ingelheim, a global pharmaceutical company founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The company is renowned for its focus on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. In Indonesia, Boehringer Ingelheim is committed to improving health and quality of life by providing innovative healthcare solutions. The company operates several branches across Indonesia, ensuring a strong local presence and accessibility to its products and services. Boehringer Ingelheim Indonesia offers a range of pharmaceutical products, including treatments for respiratory diseases, cardiovascular diseases, diabetes, oncology, and central nervous system disorders. Some of its well-known product brands include Spiriva, Pradaxa, and Jardiance. Globally, Boehringer Ingelheim operates in over 100 countries, with a significant presence in Europe, the Americas, and Asia-Pacific. The company collaborates with various research institutions and healthcare organizations to advance medical research and development. It is also a member of several industry associations, contributing to the global dialogue on healthcare innovation and policy. Boehringer Ingelheim Indonesia is dedicated to sustainability and corporate responsibility, aligning with the parent company's vision of "Value through Innovation." The company aims to address unmet medical needs and enhance patient outcomes through continuous research and development efforts. With a commitment to ethical business practices and community engagement, Boehringer Ingelheim Indonesia strives to make a positive impact on society and the environment.